WO2004009622A3 - Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies - Google Patents
Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies Download PDFInfo
- Publication number
- WO2004009622A3 WO2004009622A3 PCT/EP2003/007835 EP0307835W WO2004009622A3 WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3 EP 0307835 W EP0307835 W EP 0307835W WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complexes
- cancer
- development
- diseases
- protein complexes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003281515A AU2003281515A1 (en) | 2002-07-19 | 2003-07-18 | Protein complexes of cellular networks underlying the development of cancer and other diseases |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02016109 | 2002-07-19 | ||
EP02016123.8 | 2002-07-19 | ||
EP02016128 | 2002-07-19 | ||
EP02016109.7 | 2002-07-19 | ||
EP02016111.3 | 2002-07-19 | ||
EP02016111 | 2002-07-19 | ||
EP02016123 | 2002-07-19 | ||
EP02016128.7 | 2002-07-19 | ||
EP02016427.3 | 2002-07-22 | ||
EP02016427 | 2002-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004009622A2 WO2004009622A2 (fr) | 2004-01-29 |
WO2004009622A3 true WO2004009622A3 (fr) | 2004-09-10 |
Family
ID=30773697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007835 WO2004009622A2 (fr) | 2002-07-19 | 2003-07-18 | Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003281515A1 (fr) |
WO (1) | WO2004009622A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
US12121590B2 (en) | 2023-06-06 | 2024-10-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
CA2522700A1 (fr) * | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Procedes pour traiter des maladies entrainant l'induction d'apoptose et essais de criblage |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
US10337054B2 (en) | 2004-02-02 | 2019-07-02 | Quantum-Si Incorporated | Enrichment of nucleic acid targets |
EP2286844A3 (fr) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Conjugués anticorps-médicament et procédés |
WO2005124360A2 (fr) * | 2004-06-18 | 2005-12-29 | Roche Diagnostics Gmbh | Utilisation d'une proteine tebp en tant que marqueur pour le cancer du sein |
NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2007035494A2 (fr) * | 2005-09-16 | 2007-03-29 | The Regents Of The University Of California | Induction de l'expression de puma permettant de reduire l'inflammation articulaire dans le traitement de l'arthrite |
AU2007221234A1 (en) * | 2006-02-24 | 2007-09-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor |
WO2008104805A2 (fr) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Protéines |
AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
EP2579897A1 (fr) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Anticorps et conjugués modifiés par la cystéine |
WO2012038744A2 (fr) * | 2010-09-22 | 2012-03-29 | Genome Research Limited | Détection de mutations |
EP2640727B1 (fr) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Conjugués d'anticorps alaninyl-maytansinol |
MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
WO2013130093A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline |
SI2906251T1 (en) | 2012-10-12 | 2018-01-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
KR101986404B1 (ko) | 2012-10-12 | 2019-06-07 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
EP2906250B1 (fr) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Conjugués pyrrolobenzodiazepine-anticorps anti-psma |
AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057120A1 (fr) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Conjugués anticorps - pyrrolobenzodiazépine |
AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9649390B2 (en) | 2013-03-13 | 2017-05-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
NZ710745A (en) | 2013-03-13 | 2019-03-29 | Genentech Inc | Pyrrolobenzodiazepines and conjugates thereof |
WO2015023355A1 (fr) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement |
WO2015052532A1 (fr) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Conjugués anticorps-pyrrolobenzodiazépines |
EP3054985B1 (fr) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépine |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック, インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
EP3193940A1 (fr) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazépines et leurs conjugués |
WO2016040825A1 (fr) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés |
AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
CA2969689A1 (fr) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Composes d'amine quaternaire et conjugues anticorps-medicament de ceux-ci |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
US11130986B2 (en) * | 2015-05-20 | 2021-09-28 | Quantum-Si Incorporated | Method for isolating target nucleic acid using heteroduplex binding proteins |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017165734A1 (fr) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
EP3465221B1 (fr) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site |
US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (ja) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート |
EP3299456A1 (fr) * | 2016-09-26 | 2018-03-28 | Université de Strasbourg | Gène dgkk recombinant pour thérapie génique du syndrome x-fragile |
CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
CA3047683C (fr) | 2017-02-08 | 2020-03-10 | Adc Therapeutics Sa | Conjugues anticorps-pyrrolobenzodiazepine |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
LT3612537T (lt) | 2017-04-18 | 2022-10-10 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
BR112019021880A2 (pt) | 2017-04-20 | 2020-06-02 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo anti-axl-droga |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
LT3668874T (lt) | 2017-08-18 | 2022-03-25 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
WO2020219504A1 (fr) * | 2019-04-23 | 2020-10-29 | The Regents Of The University Of California | Modulation de la survie de cellules thérapeutiques et procédés, cellules et acides nucléiques associés à celles-ci |
CA3159566A1 (fr) | 2019-10-29 | 2021-05-06 | Quantum-Si Incorporated | Pompage peristaltique de fluides et procedes, systemes et dispositifs associes |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2024138128A2 (fr) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Conjugués d'agent de dégradation de céréblon et leurs utilisations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053312A1 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides |
WO2002092626A2 (fr) * | 2001-05-15 | 2002-11-21 | Cellzome Ag | Complexe de polyadenylation et de clivage et arnm precurseur |
-
2003
- 2003-07-18 WO PCT/EP2003/007835 patent/WO2004009622A2/fr not_active Application Discontinuation
- 2003-07-18 AU AU2003281515A patent/AU2003281515A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053312A1 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides |
WO2002092626A2 (fr) * | 2001-05-15 | 2002-11-21 | Cellzome Ag | Complexe de polyadenylation et de clivage et arnm precurseur |
Non-Patent Citations (6)
Title |
---|
BAUMANN PETER ET AL: "Pot1, the putative telomere end-binding protein in fission yeast and humans", SCIENCE (WASHINGTON D C), vol. 292, no. 5519, 11 May 2001 (2001-05-11), pages 1171 - 1175, XP002261020, ISSN: 0036-8075 * |
BLACKBURN ELIZABETH H: "Switching and signaling at the telomere", CELL, vol. 106, no. 6, 21 September 2001 (2001-09-21), pages 661 - 673, XP002261021, ISSN: 0092-8674 * |
GAVIN A-C ET AL: "Functional organization of the yeast proteome by systematic analysis of protein complexes", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, January 2002 (2002-01-01), pages 141 - 147, XP002958851, ISSN: 0028-0836 * |
HO Y ET AL: "Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, 10 January 2002 (2002-01-10), pages 180 - 183, XP002250082, ISSN: 0028-0836 * |
KUMAR ANUJ ET AL: "Protein complexes take the bait.", NATURE. ENGLAND 10 JAN 2002, vol. 415, no. 6868, 10 January 2002 (2002-01-10), pages 123 - 124, XP002261019, ISSN: 0028-0836 * |
PAWSON^A^ ^B T ET AL: "Interaction domains: from simple binding events to complex cellular behavior", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 513, no. 1, 20 February 2002 (2002-02-20), pages 2 - 10, XP004344928, ISSN: 0014-5793 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
US12121590B2 (en) | 2023-06-06 | 2024-10-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2004009622A2 (fr) | 2004-01-29 |
AU2003281515A1 (en) | 2004-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004009622A3 (fr) | Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies | |
WO2004013180A3 (fr) | Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci | |
WO2007067730A3 (fr) | Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7 | |
WO2004029093A3 (fr) | Anticorps anti-granulocytes chimeres, humains et humainises | |
WO2003087831A3 (fr) | Proteines impliquees dans le cancer du sein | |
WO2004058171A3 (fr) | Anticorps anti-gpr64 et utilisations | |
WO2006029219A3 (fr) | Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer | |
WO2004037999A3 (fr) | Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees | |
WO2007067991A3 (fr) | Anticorps monoclonaux humains se fixant a l'o8e | |
WO2006068975A3 (fr) | Proteines de liaison specifiques de la matriptase humaine | |
WO2007005874A3 (fr) | Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1) | |
WO2007038637A3 (fr) | Anticorps monoclonaux humains diriges contre cd70 | |
WO2005000901A3 (fr) | Anticorps specifiques de cd20 et leurs methodes d'utilisation | |
WO2007092640A3 (fr) | Anticorps qui se lient à par-2 | |
WO2004092215A3 (fr) | Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine | |
WO2005003298A3 (fr) | Resultat de l'utilisation d'agents therapeutiques succedanes dans l'immunotherapie a base d'anti-ctla-4 | |
WO2003076592A3 (fr) | Nouvelle methode d'administration et de synthese intracellulaire de molecules sirna | |
WO2003099205A3 (fr) | Traitement du carcinome renal a l'aide d'anticorps diriges contre le recepteur du facteur de croissance epidermique | |
WO2001068708A3 (fr) | ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a) | |
WO2004094473A3 (fr) | Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1) | |
IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
WO2004099388A3 (fr) | Complexes de polypeptides cbl-b et methodes associees | |
WO2004094476A3 (fr) | Compositions et methodes se rapportant a stop-1 | |
WO2004069860A3 (fr) | Proteines conjuguees a isg15 | |
WO2001007479A3 (fr) | Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |